RealWorld Dynamix™: Progressive Forms of MS US 2018 Spotlight
The Institute for Clinical and Economic Review (ICER) released their draft background and scope document on October 31st in support of their evaluation of the health and economic outcomes of Novartis’ Mayzent (siponimod) for the treatment of secondary progressive multiple sclerosis (SPMS). According to the recently published RealWorld Dynamix™: Progressive Forms of Multiple Sclerosis (US) audit, ICER’s recognition of progressive disease as “active” or “not active” is a clinically relevant distinction due to the significant differences in patient demographics, disability progression, and treatment patterns between the active and not active SPMS subgroups.
Contact [email protected] for more information about the highlighted report or to see if your company already has access.
All company, brand or product names and logos in this document are trademarks of their respective holders.